For patients on highly emetogenic chemotherapy, are you adopting a DEX-sparing or DEX-free approach with NEPA plus olanzapine?

Meng et al. DOI: 10.1200/JCO-26-01029

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

How do you approach prophylactic antibiotics in patients who continue to have recurrent neutropenic fever following chemotherapy for solid tumors despite chemotherapy dose reduction and growth factor support?

How should cisplatin be used in head and neck cancer patients with sensorineural hearing loss?

How would you manage the side effects/toxicities (e.g., pain, swelling, erythema) of adjuvant EBRT to the ear for cutaneous SCC?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.